Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 26 (5), 865-875
- https://doi.org/10.1016/j.bbmt.2019.11.027
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 31 references indexed in Scilit:
- Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemiaLeukemia, 2019
- Chimeric Antigen Receptor TherapyThe New England Journal of Medicine, 2018
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemiaAmerican Journal of Hematology, 2018
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaNature Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaThe New England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2018
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJournal of Clinical Oncology, 2017
- Recent advances in T‐cell immunotherapy for haematological malignanciesBritish Journal of Haematology, 2016
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014